---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-014494"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2022-04-14T23:59:59+00:00"
generated_at: "2026-06-26T07:24:39.068184+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Imara cuts 83% of workforce, ends all pipeline programs, reviews strategic options

## Summary
- Workforce reduction of ~83% leaves only 6 full-time employees; substantially complete by Q2 2022.
- Discontinues tovinontrine (IMR-687) in sickle cell, beta-thalassemia, and heart failure with preserved ejection fraction.
- Also discontinues development of IMR-261; company starts comprehensive strategic review to maximize shareholder value.
- One-time restructuring charge of $2.0-2.2 million expected in Q2 2022 for severance and benefits.
- Chief Medical Officer Kenneth Attie, M.D. departs effective April 20, 2022.

## SEC filing metadata
- accession: 0001564590-22-014494
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2022-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.0, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000156459022014494/0001564590-22-014494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000156459022014494/imra-8k_20220405.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-014494
- JSON: https://secwatch.observer/filing/0001564590-22-014494.json
- Plain text: https://secwatch.observer/filing/0001564590-22-014494.txt

## Key facts
- Executive change
  Kenneth Attie departed as Chief Medical Officer at Enliven Therapeutics, Inc..
  - Action: separated
  - Role: Chief Medical Officer
  source text: Kenneth Attie, M.D., the Company’s Chief Medical Officer will separate from the Company effective April 20, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000156459022014494/0001564590-22-014494-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.